Abstract: A novel anti-CD73 antibody and use thereof are provided. The anti-CD73 antibody can be used for treating tumors, particularly tumors expressing CD73 (CD73+) on the surface of tumor cells.

Abstract: Novel compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity, as well as method for their preparation and use are provided. Specifically, compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates, as well as method for their preparation and use are provided. Where, W is C; X3 is N or CRX3; X4 is N or CRX4; X5 is N or CRX5; X6 is N or CRX6.

Abstract: Disclosed are an anti-human PVRIG antibody or an antigen-binding fragment thereof, as well as an application thereof in the preparation of a medicament for treating diseases, such as cancer, which are related to the abnormal expression of PVRIG.

Abstract: An antibody-drug conjugate targeting HER2, HER3 and EGFR, and a pharmaceutically acceptable salt, a hydrate, a solvate or an isotopically labelled analogue thereof, the use thereof, and a preparation method therefor.

Abstract: The present application provides a pharmaceutical composition, comprising an anti-CLDN18.2 antibody-drug conjugate, a buffer, a stabilizer and a surfactant. The present application further provides a method for preparing the pharmaceutical composition and use of the pharmaceutical composition.

Abstract: Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.

Abstract: Described herein are crystalline forms of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof. Also described herein are pharmaceutical formulations of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof.

Abstract: A leak-proof atomizing component, which comprises an atomizing head and a atomizing core; The atomizing head is provided with a liquid return hole that is connected with the peripheral bottle body; When the return liquid hole is only one, the diameter of the return liquid hole is the first preset value, so that the liquid in the peripheral bottle cannot continuously flow out from the return liquid hole when the peripheral bottle is poured; When the return liquid hole is multiple, the diameter of the return liquid hole is the second preset value, so that when the peripheral bottle body is poured, the liquid in the peripheral bottle body cannot continuously flow out of the return liquid hole due to the existence of liquid tension. By optimizing the return hole, the component avoids continuous liquid out flow through the return hole when the bottle is poured.

Abstract: The present invention relates to a novel molecule with protein tyrosine kinase inhibitory activity, and the synthesis and usage thereof. Specifically, the present invention relates to compound by formula A, pharmaceutically acceptable salts, hydrates or solvates thereof, and the synthesis and usage thereof.

Abstract: Compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity, as well as method for their preparation and use are provided. Specifically, a compound of Formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a stereoisomer thereof or isotopic derivative thereof, as well as method for their preparation and use are provided.

Abstract: This application provide a data processing method performed by a computer device. The method includes: receiving a request for a cross-regional resource transfer service submitted by a first user at a first terminal to a second user at a second terminal; setting a state machine of the cross-regional resource transfer service to a first state according to a state identifier in the request; executing a first service logic corresponding to the first state; adjusting the state machine to a second state according to an execution result of the first service logic; executing a second service logic corresponding to the second state; and returning a service execution result of the cross-regional resource transfer service to the first user at the first terminal and the second user at the second terminal according to an execution result of the second service logic when the second state is a termination state.

Abstract: Compounds that inhibit Protein Arginine N-Methyl Transferase 5(PRMT5) activity, as well as method for their preparation and use are provided. Specifically, compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates, as well as method for their preparation and use are provided.

Abstract: The present application relates to an anti-Nectin-4 antibody, a drug conjugate and a preparation method and use thereof, which can be effectively used for the treatment and/or prevention of Nectin-4 positive tumors, including cancers, such as breast cancer and bladder cancer.

Abstract: Embodiments of this application provide a data processing method and apparatus, a computer device, and a readable storage medium.

Abstract: Compounds that inhibit Protein Arginine N-Methyl Transferase 5(PRMT5) activity, as well as method for their preparation and use are provided. Specifically, compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates, as well as method for their prepation and use are provided.

Abstract: The present disclosure relates to an electronic device and its execution method and a computer-readable medium. An electronic device includes: a memory, in which instructions are stored; and a processor, configured to execute the instructions stored in the memory to cause the electronic device to execute the following operations: determining a plurality of different time periods; collecting information about the viewing habits for the plurality of different time periods; and generating a recommended list in real time for each of the plurality of different time periods based on the collected information; wherein the recommended list for each time period is based on the collected information about the viewing habits for that time period of that day.

Abstract: The present application provides an anti-CLDN18.2 antibody and an antibody-drug conjugate prepared from the antibody. The antibody or the antibody-drug conjugate can effectively treat CLDN18.2 positive tumors, comprising but not limited to cancers represented by gastric cancer and pancreatic cancer.

Abstract: Described herein are crystalline forms of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof. Also described herein are pharmaceutical formulations of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof.

Abstract: A network device receives, from multiple smart cameras located at different road segments of multiple real-world road segments, first data describing a location and configuration of each of the multiple real-world road segments, and second data describing movement of one or more objects at each of the multiple real-world road segments. The network device generates multiple virtual road segments based on the first data, wherein each of the multiple virtual road segments describes one of the multiple real-world road segments; and uses a physics engine to simulate, based on the generated multiple virtual road segments and the second data, movement of vehicles or pedestrians through the multiple real-world road segments to analyze traffic characteristics, trends or events. The network device generates road segment alterations for reconfiguring one or more of the multiple real-world road segments based on the analysis of the traffic characteristics, trends, or events.